Email updates

Keep up to date with the latest news and content from BMC Nephrology and BioMed Central.

Open Access Research article

Outpatient red blood cell transfusion payments among patients on chronic dialysis

Matthew Gitlin1*, J Andrew Lee1, David M Spiegel2, Jeffrey L Carson3, Xue Song4, Brian S Custer5, Zhun Cao4, Katherine A Cappell4, Helen V Varker4, Shaowei Wan1 and Akhtar Ashfaq1

Author Affiliations

1 Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA, USA

2 University of Colorado, Denver, CO, USA

3 UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, USA

4 Truven Health Analytics, Cambridge, MA, USA

5 Blood Systems Research Institute, San Francisco, CA, USA

For all author emails, please log on.

BMC Nephrology 2012, 13:145  doi:10.1186/1471-2369-13-145

Published: 2 November 2012

Abstract

Background

Payments for red blood cell (RBC) transfusions are separate from US Medicare bundled payments for dialysis-related services and medications. Our objective was to examine the economic burden for payers when chronic dialysis patients receive outpatient RBC transfusions.

Methods

Using Truven Health MarketScan® data (1/1/02-10/31/10) in this retrospective micro-costing economic analysis, we analyzed data from chronic dialysis patients who underwent at least 1 outpatient RBC transfusion who had at least 6 months of continuous enrollment prior to initial dialysis claim and at least 30 days post-transfusion follow-up. A conceptual model of transfusion-associated resource use based on current literature was employed to estimate outpatient RBC transfusion payments. Total payments per RBC transfusion episode included screening/monitoring (within 3 days), blood acquisition/administration (within 2 days), and associated complications (within 3 days for acute events; up to 45 days for chronic events).

Results

A total of 3283 patient transfusion episodes were included; 56.4% were men and 40.9% had Medicare supplemental insurance. Mean (standard deviation [SD]) age was 60.9 (15.0) years, and mean Charlson comorbidity index was 4.3 (2.5). During a mean (SD) follow-up of 495 (474) days, patients had a mean of 2.2 (3.8) outpatient RBC transfusion episodes. Mean/median (SD) total payment per RBC transfusion episode was $854/$427 ($2,060) with 72.1% attributable to blood acquisition and administration payments. Complication payments ranged from mean (SD) $213 ($168) for delayed hemolytic transfusion reaction to $19,466 ($15,424) for congestive heart failure.

Conclusions

Payments for outpatient RBC transfusion episodes were driven by blood acquisition and administration payments. While infrequent, transfusion complications increased payments substantially when they occurred.

Keywords:
Dialysis; Red blood cell transfusions; Payers; Cost